Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 16 December 2025

Oceaneering International (OII) Stock News Today: Why Shares Fell on Dec. 16, 2025 — Forecasts, Analyst Targets, and What Investors Are Watching

Oceaneering International (OII) Stock News Today: Why Shares Fell on Dec. 16, 2025 — Forecasts, Analyst Targets, and What Investors Are Watching

Oceaneering International, Inc. (NYSE: OII) stock slid sharply on Tuesday, December 16, 2025, a move that put the offshore-technology and subsea robotics specialist back in the spotlight after a choppy stretch in recent sessions. In afternoon trading, OII was around $24.21, down about 6.4% on the day, after opening near $25.57 and trading between $23.89 and $25.66. StockAnalysis The drop comes as investors weigh a mix of factors: a notable one-day pullback, a generally cautious “Hold” stance from many Wall Street analysts, and a company outlook that points to 2026 growth led by its defense-focused ADTech segment—with seasonal softness expected
16 December 2025
····
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics Incorporated (NASDAQ: CORT) ended Tuesday, December 16, 2025, sharply lower after a strong 2025 run that had pushed expectations—and valuation—into the spotlight. Shares closed at $79.44, down $7.86 (about 9%) from the prior close, after trading as low as $78.84 on the day. The day’s narrative around Corcept Therapeutics stock wasn’t driven by a single blockbuster headline like an FDA decision or a clinical-trial halt. Instead, it was a classic “high-expectations” session: fresh sell-side coverage, valuation-focused commentary, and investors recalibrating risk ahead of a major FDA catalyst for relacorilant later this month. Below is a complete roundup of
16 December 2025
·····
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Inc. (NYSE: ABBV) is trading lower on Tuesday, December 16, 2025, after a strong run earlier in the quarter and a Monday close that kept the stock near the upper end of its 52‑week range. As of 17:54 UTC on Dec. 16, ABBV was at $222.44, down $5.01 (-2.20%) on the session, with an intraday range of $222.44 to $228.00. Today’s AbbVie coverage is being driven less by a single blockbuster headline and more by the familiar mix of Wall Street recalibration and pipeline expectations: Bank of America trimmed its price target, while fresh pipeline-focused analysis reiterated the thesis
16 December 2025
·····
Compass Inc stock COMP: Latest news, analyst forecasts, and key catalysts on December 16 2025

Compass Inc stock COMP: Latest news, analyst forecasts, and key catalysts on December 16 2025

Compass Inc stock (NYSE: COMP) is back in the spotlight on December 16, 2025, as investors juggle a cocktail of real-estate industry disruption, Big Tech “portal wars,” and a major consolidation bet that could reshape U.S. residential brokerage. By midday Tuesday, COMP was trading around $10.76 after opening at $10.42, with an intraday range roughly $10.28–$10.76 on volume above 2.3 million shares. That price action matters because it comes immediately after a sharp volatility spike tied to a single unnerving question: What happens to real-estate search traffic (and lead economics) if Google decides it wants a bigger slice? Below is
16 December 2025
····
Lumentum (LITE) Stock News Today: BofA Raises Price Target to $375 as AI Photonics Boom Keeps Shares Volatile

Lumentum (LITE) Stock News Today: BofA Raises Price Target to $375 as AI Photonics Boom Keeps Shares Volatile

Lumentum Holdings Inc. (NASDAQ: LITE) is back in the spotlight on Tuesday, December 16, 2025, as a fresh wave of analyst commentary and valuation debate collides with sharp intraday swings in the share price. As of the latest trade update, Lumentum stock is at $318.60, down $16.09 (-4.81%) on the day, after trading between $310.31 and $338.00. The pullback doesn’t erase what’s been a powerful run tied to one dominant theme: AI-driven data center expansion is pushing the networking stack toward photonics, and Lumentum sells core optical components that sit right in the middle of that shift. Below is a
16 December 2025
····
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. (NYSE: PFE) shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the mid-$26s and just under $25. The market’s message was clear: Pfizer’s transition away from pandemic-era revenue is still a work in progress, and 2026 is shaping up as another “bridge year” where lower COVID-19 sales and patent expirations pressure results—partly
16 December 2025
·····
Warner Bros. Discovery Series A Stock (NASDAQ: WBD) on Dec. 16, 2025: Takeover Battle, Latest News, Analyst Forecasts, and What Comes Next

Warner Bros. Discovery Series A Stock (NASDAQ: WBD) on Dec. 16, 2025: Takeover Battle, Latest News, Analyst Forecasts, and What Comes Next

NEW YORK — Warner Bros. Discovery, Inc. Series A shares (NASDAQ: WBD) are trading like a merger-arbitrage ticker rather than a traditional media stock on Tuesday, Dec. 16, 2025, with the price effectively “pinned” near $30 as investors handicap two competing endgames: Paramount Skydance’s $30-per-share all-cash tender offer versus Netflix’s prior agreement to acquire key WBD assets at a $27.75 per-share implied value. Netflix+1 As of the latest available quote Tuesday, WBD traded around $29.25, down modestly on the day, after touching an intraday high near $29.69. That sub-$30 trading level is the market’s way of pricing in a central
16 December 2025
·······
Texas Instruments (TXN) Stock News Today: Goldman Sachs Downgrade, Sherman Fab Ramp, and Wall Street Forecasts (Dec. 16, 2025)

Texas Instruments (TXN) Stock News Today: Goldman Sachs Downgrade, Sherman Fab Ramp, and Wall Street Forecasts (Dec. 16, 2025)

Texas Instruments Incorporated (NASDAQ: TXN) is back in the spotlight on December 16, 2025, as investors balance two forces moving in opposite directions: near-term pressure on the earnings story (highlighted by a high-profile Wall Street downgrade) and long-term confidence in the company’s U.S. manufacturing buildout, including a major Sherman, Texas production milestone expected this week. With TXN trading modestly lower intraday, today’s coverage centers on whether Texas Instruments’ aggressive capacity investments—once framed as a strategic advantage—could temporarily become a drag on margins, while the analog semiconductor cycle recovers more slowly than hoped. TXN stock price action today (December 16, 2025)
16 December 2025
····
Cleveland-Cliffs Stock (NYSE: CLF) on Dec. 16, 2025: Credit Downgrade, Steel Market Shifts, and the 2026 Profitability Debate

Cleveland-Cliffs Stock (NYSE: CLF) on Dec. 16, 2025: Credit Downgrade, Steel Market Shifts, and the 2026 Profitability Debate

Cleveland-Cliffs Inc. (NYSE: CLF) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a classic “steel-cycle” tug-of-war: improving operating tailwinds versus balance-sheet pressure. In Tuesday’s trading, CLF stock hovered around $12.85, modestly higher on the day, after opening near $12.76 and trading roughly between $12.69 and $12.94. The near-term narrative for Cleveland-Cliffs stock is being shaped by three overlapping themes: Below is a detailed look at the latest Cleveland-Cliffs news, forecasts, and analyst views as of 12/16/2025—and what market participants are watching next. Why Cleveland-Cliffs stock is “eventful” right now Cleveland-Cliffs is not just another steel
16 December 2025
··
Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck & Co., Inc. (NYSE: MRK) stock was among the biggest drags on the Dow Jones Industrial Average in Tuesday’s session (December 16, 2025), with shares trading lower as investors weighed broad market pressure alongside a fast-moving set of company-specific catalysts—ranging from regulatory momentum for Winrevair to ongoing efforts to protect Keytruda ahead of looming patent headwinds. MarketWatch+1 As of the latest trade at 16:41 UTC, Merck shares were $98.05, down 2.21% on the day, after trading between $96.85 and $100.49. Merck stock price action on Dec. 16: a Dow-weighted drop with no single headline Merck’s decline mattered more than
16 December 2025
···
IREN Limited Stock (NASDAQ: IREN) News Today: Why Shares Are Falling, What Analysts Forecast, and How the Microsoft AI Deal Shapes 2026 (Dec. 16, 2025)

IREN Limited Stock (NASDAQ: IREN) News Today: Why Shares Are Falling, What Analysts Forecast, and How the Microsoft AI Deal Shapes 2026 (Dec. 16, 2025)

IREN Limited stock is back in the spotlight on December 16, 2025, as the high-flying “AI infrastructure” trade collides with a sharp momentum pullback — even while the company continues to point to a massive long-term runway from its GPU cloud pivot and headline-grabbing Microsoft agreement. As of 16:39 UTC on Dec. 16, IREN was trading around $34.19, down about 3.6% on the session after opening near $34.83, with an intraday range of roughly $33.38 to $35.84 and volume above 22 million shares. This comes a day after a steep selloff: IREN shares fell 11.59% on Monday (Dec. 15), extending
16 December 2025
·····
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock (NYSE: JNJ) is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could clarify the company’s 2026 trajectory. StockAnalysis+1 Below is what’s moving Johnson & Johnson shares right now, what Wall Street is forecasting, and the key dates JNJ stock watchers have on the calendar. JNJ stock price check: what’s happening on Dec. 16, 2025 As of late morning U.S. time on December 16, JNJ stock was trading around the $211–$212 area, down
16 December 2025
·····
1 … 149 150 151 152 153 … 282

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Go toTop